Nordic Nanovector ASA announced the appointment of Sandra Jonsson, PhD, MBA as Chief Operating Officer. Dr. Jonsson will start on 10 January 2022 and takes over from Marco Renoldi, MD, who is retiring from the role but will remain as a consultant to the company. Dr. Jonsson joins Nordic Nanovector from Alexion Pharmaceuticals, at which she was Senior Director, Commercial International (prior to its acquisition by AstraZeneca in 2021) and before this, she was Head of Commercial Strategy & Operations in Region Europe at Shire (prior to its acquisition by Takeda in 2019). Previously Dr. Jonsson spent 12 years at Novartis in a range of strategic and operational Global roles of increasing responsibility.